Risk-reduction Surgery Decisions in High-risk Women Seen for Genetic Counseling

Overview

Journal J Genet Couns

Publisher Wiley

Specialty Genetics

Date 2006 Jan 3

PMID 16388328

Citations 22

Authors

Jessica A Ray

Lois J Loescher

Molly Brewer

Affiliations

Soon will be listed here.

Abstract

Women at greatest risk for hereditary breast and ovarian cancer may consider prophylactic removal of breasts or ovaries as a risk-reduction measure. This report describes uptake of risk-reduction mastectomy (RRM), risk-reduction oophorectomy (RRO), and related factors in 62 high-risk women who received genetic counseling. Seven (11%) participants underwent RRM and 13 (21%) underwent RRO. Of these women, 37% did not have BRCA testing, suggesting other factors influence decisions to undergo surgery. Women who had indicated (pre-genetic counseling) their intent not to have surgery chose not to have surgery. Information received during genetic counseling that women perceived as being most important for influencing risk-reduction surgery decisions was BRCA test result (positive or negative), followed by discussion of family cancer history. Reasons for indecision about risk-reduction surgery included genetic testing results, concerns about surgery, timing in life, and early menopause. The findings enhance our understanding of information that is helpful to women considering this surgery.

Citing Articles

Optimization of Timing for Risk-Reducing Salpingectomy and Oophorectomy.

Pennington K, Pugh S, Huh W, Walker J, Jewell E, Havrilesky L Obstet Gynecol. 2024; 145(1):21-30.

PMID: 39509704 PMC: 11637911. DOI: 10.1097/AOG.0000000000005781.

Risk-management decision-making data from a community-based sample of racially diverse women at high risk of breast cancer: rationale, methods, and sample characteristics of the Daughter Sister Mother Project survey.

Padamsee T, Bijou C, Swinehart-Hord P, Hils M, Muraveva A, Meadows R Breast Cancer Res. 2024; 26(1):8.

PMID: 38212792 PMC: 10785448. DOI: 10.1186/s13058-023-01753-x.

Breast Cancer Risk and Breast-Cancer-Specific Mortality following Risk-Reducing Salpingo-Oophorectomy in Carriers: A Systematic Review and Meta-Analysis.

Gaba F, Blyuss O, Tan A, Munblit D, Oxley S, Khan K Cancers (Basel). 2023; 15(5).

PMID: 36900415 PMC: 10001253. DOI: 10.3390/cancers15051625.

Attitudes towards risk-reducing early salpingectomy with delayed oophorectomy for ovarian cancer prevention: a cohort study.

Gaba F, Blyuss O, Chandrasekaran D, Osman M, Goyal S, Gan C BJOG. 2020; 128(4):714-726.

PMID: 32803845 PMC: 7614715. DOI: 10.1111/1471-0528.16424.

Involvement and Influence of Healthcare Providers, Family Members, and Other Mutation Carriers in the Cancer Risk Management Decision-Making Process of BRCA1 and BRCA2 Mutation Carriers.

Puski A, Hovick S, Senter L, Toland A J Genet Couns. 2018; 27(5):1291-1301.

PMID: 29594659 PMC: 6612901. DOI: 10.1007/s10897-018-0254-4.

References

Moller P, Borg A, Evans D, Haites N, Reis M, Vasen H . Survival in prospectively ascertained familial breast cancer: analysis of a series stratified by tumour characteristics, BRCA mutations and oophorectomy. Int J Cancer. 2002; 101(6):555-9. DOI: 10.1002/ijc.10641. View

Hallowell N . A qualitative study of the information needs of high-risk women undergoing prophylactic oophorectomy. Psychooncology. 2001; 9(6):486-95. DOI: 10.1002/1099-1611(200011/12)9:6<486::aid-pon478>3.0.co;2-y. View

Schrag D, Kuntz K, Garber J, Weeks J . Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations. JAMA. 2000; 283(5):617-24. DOI: 10.1001/jama.283.5.617. View

Lynch H, Casey M . Current status of prophylactic surgery for hereditary breast and gynecologic cancers. Curr Opin Obstet Gynecol. 2001; 13(1):25-30. DOI: 10.1097/00001703-200102000-00004. View

Lerman C, Hughes C, Croyle R, Main D, Durham C, Snyder C . Prophylactic surgery decisions and surveillance practices one year following BRCA1/2 testing. Prev Med. 2000; 31(1):75-80. DOI: 10.1006/pmed.2000.0684. View

Smith R, Saslow D, Sawyer K, Burke W, Costanza M, Evans 3rd W . American Cancer Society guidelines for breast cancer screening: update 2003. CA Cancer J Clin. 2003; 53(3):141-69. DOI: 10.3322/canjclin.53.3.141. View

Kauff N, Satagopan J, Robson M, Scheuer L, Hensley M, Hudis C . Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2002; 346(21):1609-15. DOI: 10.1056/NEJMoa020119. View

Ghosh K, Hartmann L . Current status of prophylactic mastectomy. Oncology (Williston Park). 2002; 16(10):1319-25; discussion 1325, 1329-30, 1332. View

Morice P, Pautier P, Delaloge S . Prophylactic surgery in patients with inherited risk of ovarian cancer. Gynecol Oncol. 2001; 83(2):445-7. DOI: 10.1006/gyno.2001.6257. View

10.

Wacholder S, Struewing J, Hartge P, Greene M, Tucker M . Breast cancer risks for BRCA1/2 carriers. Science. 2004; 306(5705):2187-91. View

11.

Fry A, Rush R, Busby-Earle C, Cull A . Deciding about prophylactic oophorectomy: what is important to women at increased risk of ovarian cancer?. Prev Med. 2001; 33(6):578-85. DOI: 10.1006/pmed.2001.0924. View

12.

Petit J, Greco M . Quality control in prophylactic mastectomy for women at high risk of breast cancer. Eur J Cancer. 2001; 38(1):23-6. DOI: 10.1016/s0959-8049(01)00351-3. View

13.

Scheuer L, Kauff N, Robson M, Kelly B, Barakat R, Satagopan J . Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol. 2002; 20(5):1260-8. DOI: 10.1200/JCO.2002.20.5.1260. View

14.

Rebbeck T, Levin A, Eisen A, Snyder C, Watson P, Cannon-Albright L . Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst. 1999; 91(17):1475-9. DOI: 10.1093/jnci/91.17.1475. View

15.

Rogozinska-Szczepka J, Utracka-Hutka B, Grzybowska E, Maka B, Nowicka E, Smok-Ragankiewicz A . BRCA1 and BRCA2 mutations as prognostic factors in bilateral breast cancer patients. Ann Oncol. 2004; 15(9):1373-6. DOI: 10.1093/annonc/mdh352. View

16.

Claus E, Risch N, Thompson W . Genetic analysis of breast cancer in the cancer and steroid hormone study. Am J Hum Genet. 1991; 48(2):232-42. PMC: 1683001. View

17.

Colditz G, Willett W, Hunter D, Stampfer M, Manson J, Hennekens C . Family history, age, and risk of breast cancer. Prospective data from the Nurses' Health Study. JAMA. 1993; 270(3):338-43. View

18.

Meijers-Heijboer H, van Geel B, van Putten W, Henzen-Logmans S, Seynaeve C, BARTELS C . Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2001; 345(3):159-64. DOI: 10.1056/NEJM200107193450301. View

19.

Hartmann L, Degnim A, Schaid D . Prophylactic mastectomy for BRCA1/2 carriers: progress and more questions. J Clin Oncol. 2004; 22(6):981-3. DOI: 10.1200/JCO.2004.01.925. View

20.

Thull D, Vogel V . Recognition and management of hereditary breast cancer syndromes. Oncologist. 2004; 9(1):13-24. DOI: 10.1634/theoncologist.9-1-13. View